Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Ambry Genetics | RCV004969506 | SCV005523478 | uncertain significance | Inborn genetic diseases | 2024-11-13 | criteria provided, single submitter | clinical testing | The c.2743G>A (p.E915K) alteration is located in exon 20 (coding exon 20) of the TTC21B gene. This alteration results from a G to A substitution at nucleotide position 2743, causing the glutamic acid (E) at amino acid position 915 to be replaced by a lysine (K). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
| Labcorp Genetics |
RCV005221143 | SCV005869758 | uncertain significance | Jeune thoracic dystrophy; Nephronophthisis | 2024-12-14 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamic acid, which is acidic and polar, with lysine, which is basic and polar, at codon 915 of the TTC21B protein (p.Glu915Lys). This variant is present in population databases (rs748527082, gnomAD 0.003%). This variant has not been reported in the literature in individuals affected with TTC21B-related conditions. Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed for this missense variant. However, the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on TTC21B protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |